Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy.

Patel K, Siraj S, Smith C, Nair M, Vishwanatha JK, Basha R.

Crit Rev Oncog. 2019;24(2):105-118. doi: 10.1615/CritRevOncog.2019031417.

PMID:
31679206
2.

Ovarian cancer: Current status and strategies for improving therapeutic outcomes.

Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, Basha R.

Cancer Med. 2019 Nov;8(16):7018-7031. doi: 10.1002/cam4.2560. Epub 2019 Sep 27. Review.

3.

Diversity in the Era of Precision Medicine - From Bench to Bedside Implementation.

Mamun A, Nsiah NY, Srinivasan M, Chaturvedula A, Basha R, Cross D, Jones HP, Nandy K, Vishwanatha JK.

Ethn Dis. 2019 Jul 18;29(3):517-524. doi: 10.18865/ed.29.3.517. eCollection 2019 Summer.

PMID:
31367173
4.

An Institutional Coordinated Plan for Effective Partnerships to Achieve Health Equity and Biomedical Workforce Diversity.

Vishwanatha JK, Basha R, Nair M, Jones HP.

Ethn Dis. 2019 Feb 21;29(Suppl 1):129-134. doi: 10.18865/ed.29.S1.129. eCollection 2019.

5.

In vivo imaging and biodistribution of near infrared dye loaded brain-metastatic-breast-cancer-cell-membrane coated polymeric nanoparticles.

Kumar P, Treuren TV, Ranjan AP, Chaudhary P, Vishwanatha JK.

Nanotechnology. 2019 Jun 28;30(26):265101. doi: 10.1088/1361-6528/ab0f46. Epub 2019 Mar 13.

PMID:
30865940
6.

Novel Survivin Inhibitor for Suppressing Pancreatic Cancer Cells Growth via Downregulating Sp1 and Sp3 Transcription Factors.

Hurtado M, Sankpal UT, Kaba A, Mahammad S, Chhabra J, Brown DT, Gurung RK, Holder AA, Vishwanatha JK, Basha R.

Cell Physiol Biochem. 2018;51(4):1894-1907. doi: 10.1159/000495715. Epub 2018 Nov 30.

7.

Early career biomedical grantsmanship self-efficacy: validation of an abbreviated self-assessment tool.

Harwood EM, Jones AR, Erickson D, Buchwald D, Johnson-Hemming J, Jones HP, Manson S, McGee R, Smith A, Steer CJ, Vishwanatha JK, Weber-Main AM, Okuyemi KS.

Ann N Y Acad Sci. 2019 Jun;1445(1):17-26. doi: 10.1111/nyas.13995. Epub 2018 Dec 5.

PMID:
30515830
8.

ANXA2 expression in African American triple-negative breast cancer patients.

Gibbs LD, Chaudhary P, Mansheim K, Hare RJ, Mantsch RA, Vishwanatha JK.

Breast Cancer Res Treat. 2019 Feb;174(1):113-120. doi: 10.1007/s10549-018-5030-5. Epub 2018 Nov 26.

PMID:
30478786
9.

Reciprocal regulation of pro-inflammatory Annexin A2 and anti-inflammatory Annexin A1 in the pathogenesis of rheumatoid arthritis.

Haridas V, Shetty P, Sarathkumar E, Bargale A, Vishwanatha JK, Patil V, Dinesh US.

Mol Biol Rep. 2019 Feb;46(1):83-95. doi: 10.1007/s11033-018-4448-5. Epub 2018 Nov 13.

PMID:
30426384
10.

CRISPR deletion of MIEN1 in breast cancer cells.

Van Treuren T, Vishwanatha JK.

PLoS One. 2018 Oct 4;13(10):e0204976. doi: 10.1371/journal.pone.0204976. eCollection 2018.

11.

Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.

Marrufo AM, Mathew SO, Chaudhary P, Malaer JD, Vishwanatha JK, Mathew PA.

Am J Cancer Res. 2018 Jun 1;8(6):1050-1063. eCollection 2018.

12.

Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer.

Hurtado M, Sankpal UT, Ranjan A, Maram R, Vishwanatha JK, Nagaraju GP, El-Rayes BF, Basha R.

Crit Rev Oncol Hematol. 2018 Jun;126:201-207. doi: 10.1016/j.critrevonc.2018.03.016. Epub 2018 Apr 7. Review.

PMID:
29759562
13.

Evidence-based approaches to reduce cancer health disparities: Discover, develop, deliver, and disseminate.

Desai PP, Lampe JB, Bakre SA, Basha RM, Jones HP, Vishwanatha JK.

J Carcinog. 2018 Feb 28;17:1. doi: 10.4103/jcar.JCar_13_17. eCollection 2018.

14.
15.

Optimization and scale up of microfluidic nanolipomer production method for preclinical and potential clinical trials.

Gdowski A, Johnson K, Shah S, Gryczynski I, Vishwanatha J, Ranjan A.

J Nanobiotechnology. 2018 Feb 12;16(1):12. doi: 10.1186/s12951-018-0339-0.

16.

Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer.

Gibbs LD, Vishwanatha JK.

Oncotarget. 2017 Dec 23;9(2):2697-2704. doi: 10.18632/oncotarget.23627. eCollection 2018 Jan 5.

17.

A new approach to mentoring for research careers: the National Research Mentoring Network.

Sorkness CA, Pfund C, Ofili EO, Okuyemi KS, Vishwanatha JK; NRMN team, Zavala ME, Pesavento T, Fernandez M, Tissera A, Deveci A, Javier D, Short A, Cooper P, Jones H, Manson S, Buchwald D, Eide K, Gouldy A, Kelly E, Langford N, McGee R, Steer C, Unold T, Weber-Main AM, Báez A, Stiles J, Pemu P, Thompson W, Gwathmey J, Lawson K, Johnson J, Hall M, Paulsen D, Fouad M, Smith A, Luna R, Wilson D, Adelsberger G, Simenson D, Cook A, Feliu-Mojer M, Harwood E, Jones A, Branchaw J, Thomas S, Butz A, Byars-Winston A, House S, McDaniels M, Quinn S, Rogers J, Spencer K, Utzerath E, Duplicate Of Weber-Main, Womack V.

BMC Proc. 2017 Dec 4;11(Suppl 12):22. doi: 10.1186/s12919-017-0083-8. eCollection 2017.

18.

Enhancing research careers: an example of a US national diversity-focused, grant-writing training and coaching experiment.

Jones HP, McGee R, Weber-Main AM, Buchwald DS, Manson SM, Vishwanatha JK, Okuyemi KS.

BMC Proc. 2017 Dec 4;11(Suppl 12):16. doi: 10.1186/s12919-017-0084-7. eCollection 2017.

19.

Development and Characterization of Methylene Blue Oleate Salt-Loaded Polymeric Nanoparticles and their Potential Application as a Treatment for Glioblastoma.

Castañeda-Gill JM, Ranjan AP, Vishwanatha JK.

J Nanomed Nanotechnol. 2017 Aug;8(4). pii: 449. doi: 10.4172/2157-7439.1000449. Epub 2017 Jul 31.

20.

Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain.

Gdowski AS, Ranjan A, Sarker MR, Vishwanatha JK.

Nanomedicine (Lond). 2017 Sep;12(17):2083-2095. doi: 10.2217/nnm-2017-0190. Epub 2017 Aug 14.

21.

Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials.

Gdowski AS, Ranjan A, Vishwanatha JK.

J Exp Clin Cancer Res. 2017 Aug 11;36(1):108. doi: 10.1186/s13046-017-0578-1. Review.

22.

"Curcumin-loaded Poly (d, l-lactide-co-glycolide) nanovesicles induce antinociceptive effects and reduce pronociceptive cytokine and BDNF release in spinal cord after acute administration in mice".

Pieretti S, Ranjan AP, Di Giannuario A, Mukerjee A, Marzoli F, Di Giovannandrea R, Vishwanatha JK.

Colloids Surf B Biointerfaces. 2017 Oct 1;158:379-386. doi: 10.1016/j.colsurfb.2017.07.027. Epub 2017 Jul 10.

PMID:
28719859
23.

NIH's mentoring makes progress.

Vishwanatha J, Pfund C, Ofili E, Okuyemi K.

Science. 2016 Nov 18;354(6314):840-841. No abstract available.

PMID:
27856873
24.

Exosomal Annexin II Promotes Angiogenesis and Breast Cancer Metastasis.

Maji S, Chaudhary P, Akopova I, Nguyen PM, Hare RJ, Gryczynski I, Vishwanatha JK.

Mol Cancer Res. 2017 Jan;15(1):93-105. doi: 10.1158/1541-7786.MCR-16-0163. Epub 2016 Oct 19.

25.

Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction.

Mathew SO, Chaudhary P, Powers SB, Vishwanatha JK, Mathew PA.

Oncotarget. 2016 Oct 18;7(42):68650-68661. doi: 10.18632/oncotarget.11896.

26.

MIEN1 is tightly regulated by SINE Alu methylation in its promoter.

Rajendiran S, Gibbs LD, Van Treuren T, Klinkebiel DL, Vishwanatha JK.

Oncotarget. 2016 Oct 4;7(40):65307-65319. doi: 10.18632/oncotarget.11675.

27.

Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.

Sankpal UT, Ingersoll SB, Ahmad S, Holloway RW, Bhat VB, Simecka JW, Daniel L, Kariali E, Vishwanatha JK, Basha R.

Tumour Biol. 2016 Oct;37(10):14259-14269. Epub 2016 Aug 31.

PMID:
27581819
28.

MIEN1 drives breast tumor cell migration by regulating cytoskeletal-focal adhesion dynamics.

Kpetemey M, Chaudhary P, Van Treuren T, Vishwanatha JK.

Oncotarget. 2016 Aug 23;7(34):54913-54924. doi: 10.18632/oncotarget.10798.

29.
30.

Curcumin-ER Prolonged Subcutaneous Delivery for the Treatment of Non-Small Cell Lung Cancer.

Ranjan AP, Mukerjee A, Gdowski A, Helson L, Bouchard A, Majeed M, Vishwanatha JK.

J Biomed Nanotechnol. 2016 Apr;12(4):679-88.

PMID:
27301194
31.

Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF-kB translocation to nucleus and cell cycle phase distribution.

Basha R, Connelly SF, Sankpal UT, Nagaraju GP, Patel H, Vishwanatha JK, Shelake S, Tabor-Simecka L, Shoji M, Simecka JW, El-Rayes B.

J Nutr Biochem. 2016 May;31:77-87. doi: 10.1016/j.jnutbio.2016.01.003. Epub 2016 Feb 10.

32.

Antiangiogenic mechanisms and factors in breast cancer treatment.

Castañeda-Gill JM, Vishwanatha JK.

J Carcinog. 2016 Feb 12;15:1. doi: 10.4103/1477-3163.176223. eCollection 2016. Review.

33.

Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy.

Kokate RA, Chaudhary P, Sun X, Thamake SI, Maji S, Chib R, Vishwanatha JK, Jones HP.

Nanomedicine (Lond). 2016;11(5):479-94. doi: 10.2217/nnm.15.213. Epub 2016 Feb 19.

34.

Cell surface interaction of annexin A2 and galectin-3 modulates epidermal growth factor receptor signaling in Her-2 negative breast cancer cells.

Shetty P, Bargale A, Patil BR, Mohan R, Dinesh US, Vishwanatha JK, Gai PB, Patil VS, Amsavardani TS.

Mol Cell Biochem. 2016 Jan;411(1-2):221-33. doi: 10.1007/s11010-015-2584-y. Epub 2015 Oct 5.

PMID:
26438086
35.

Role of genomics in eliminating health disparities.

Kashyap MV, Nolan M, Sprouse M, Chakraborty R, Cross D, Roby R, Vishwanatha JK.

J Carcinog. 2015 Sep 11;14:6. doi: 10.4103/1477-3163.165158. eCollection 2015. Review.

36.

Combination of 13 cis-retinoic acid and tolfenamic acid induces apoptosis and effectively inhibits high-risk neuroblastoma cell proliferation.

Shelake S, Eslin D, Sutphin RM, Sankpal UT, Wadwani A, Kenyon LE, Tabor-Simecka L, Bowman WP, Vishwanatha JK, Basha R.

Int J Dev Neurosci. 2015 Nov;46:92-9. doi: 10.1016/j.ijdevneu.2015.07.012. Epub 2015 Aug 10.

PMID:
26287661
37.

MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression.

Kpetemey M, Dasgupta S, Rajendiran S, Das S, Gibbs LD, Shetty P, Gryczynski Z, Vishwanatha JK.

Mol Cancer. 2015 Aug 15;14:156. doi: 10.1186/s12943-015-0428-8.

38.

MIEN1 promotes oral cancer progression and implicates poor overall survival.

Rajendiran S, Kpetemey M, Maji S, Gibbs LD, Dasgupta S, Mantsch R, Hare RJ, Vishwanatha JK.

Cancer Biol Ther. 2015;16(6):876-85. doi: 10.1080/15384047.2015.1040962.

39.

A nanotherapy strategy significantly enhances anticryptosporidial activity of an inhibitor of bifunctional thymidylate synthase-dihydrofolate reductase from Cryptosporidium.

Mukerjee A, Iyidogan P, Castellanos-Gonzalez A, Cisneros JA, Czyzyk D, Ranjan AP, Jorgensen WL, White AC Jr, Vishwanatha JK, Anderson KS.

Bioorg Med Chem Lett. 2015;25(10):2065-7. doi: 10.1016/j.bmcl.2015.03.091. Epub 2015 Apr 4.

40.

Enhancement of anti-tumor effect of particulate vaccine delivery system by 'bacteriomimetic' CpG functionalization of poly-lactic-co-glycolic acid nanoparticles.

Kokate RA, Thamake SI, Chaudhary P, Mott B, Raut S, Vishwanatha JK, Jones HP.

Nanomedicine (Lond). 2015;10(6):915-29. doi: 10.2217/nnm.14.144. Erratum in: Nanomedicine (Lond). 2015 May;10(10):1676.

41.

Development of biodegradable nanocarriers loaded with a monoclonal antibody.

Gdowski A, Ranjan A, Mukerjee A, Vishwanatha J.

Int J Mol Sci. 2015 Feb 12;16(2):3990-5. doi: 10.3390/ijms16023990.

42.

MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1.

Rajendiran S, Parwani AV, Hare RJ, Dasgupta S, Roby RK, Vishwanatha JK.

Mol Cancer. 2014 Nov 19;13:250. doi: 10.1186/1476-4598-13-250.

43.

ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer.

Griner NB, Young D, Chaudhary P, Mohamed AA, Huang W, Chen Y, Sreenath T, Dobi A, Petrovics G, Vishwanatha JK, Sesterhenn IA, Srivastava S, Tan SH.

Mol Cancer Res. 2015 Feb;13(2):368-79. doi: 10.1158/1541-7786.MCR-14-0275-T. Epub 2014 Oct 24.

44.

Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies.

Chaudhary P, Thamake SI, Shetty P, Vishwanatha JK.

Br J Cancer. 2014 Dec 9;111(12):2328-41. doi: 10.1038/bjc.2014.542. Epub 2014 Oct 16.

45.

c-Jun NH2-terminal kinase-induced proteasomal degradation of c-FLIPL/S and Bcl2 sensitize prostate cancer cells to Fas- and mitochondria-mediated apoptosis by tetrandrine.

Chaudhary P, Vishwanatha JK.

Biochem Pharmacol. 2014 Oct 15;91(4):457-73. doi: 10.1016/j.bcp.2014.08.014. Epub 2014 Aug 30.

46.

BSA Au clusters as a probe for enhanced fluorescence detection using multipulse excitation scheme.

Raut SL, Rich R, Fudala R, Kokate R, Kimball JD, Borejdo J, Vishwanatha JK, Gryczynski Z, Gryczynski I.

Curr Pharm Biotechnol. 2014;14(13):1139-44.

PMID:
24853092
47.

Cell surface translocation of annexin A2 facilitates glutamate-induced extracellular proteolysis.

Valapala M, Maji S, Borejdo J, Vishwanatha JK.

J Biol Chem. 2014 Jun 6;289(23):15915-26. doi: 10.1074/jbc.M113.511550. Epub 2014 Apr 17.

48.

Nanobiosensors: role in cancer detection and diagnosis.

Gdowski A, Ranjan AP, Mukerjee A, Vishwanatha JK.

Adv Exp Med Biol. 2014;807:33-58. doi: 10.1007/978-81-322-1777-0_4. Review.

PMID:
24619617
49.

Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation.

Ranjan AP, Mukerjee A, Helson L, Vishwanatha JK.

J Nanobiotechnology. 2013 Dec 14;11:40. doi: 10.1186/1477-3155-11-40.

50.

Establishment of human retinal microvascular endothelial cells with extended life-span.

Kashyap MV, Ranjan AP, Shankardas J, Vishwanatha JK.

In Vivo. 2013 Nov-Dec;27(6):685-94.

PMID:
24292569

Supplemental Content

Loading ...
Support Center